Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
BACKGROUND
Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable Stage Ⅲ non-small cell lung cancer (NSCLC). Here, we report the final analysis results of...
Zi-Ming Li, L. Wu, W.-X. Wang et al.· Annals of Oncology· 0 citations
PURPOSE
MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-ge...
Zi-Ming Li, Xiao-Rong Dong, Yan Yu et al.· Journal of Clinical Oncology· 0 citations
Abstract Background The incidence of early-onset colorectal cancer (EOCRC) is rising globally, presenting unique clinical challenges due to its aggressive nature compared to late-onset cases. While obesity is a known risk factor for carcinogenesis, its prognostic significance specifically on the EOCRC population remain...
Jin-Lin Cai, Tuo-Yang Li, Jing-Rong Weng et al.· The Oncologist· 0 citations
The role of Olvi-Vec as an oncolytic immunotherapy for cancer treatment warrants additional study, and the clinical effect observed in this patient may be related to Olvi-Vec-mediated changes in the tumor microenvironment, potentially leading to platinum re-sensitization.
Yun Chen, Zhi-Quan Qin, Zi-Ming Li et al.· Frontiers in Oncology· 0 citations
The BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.
Jing Sun, Zhengqi Cao, Yueping Jin et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.